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OBJECTIVE — To investigate relationships between baseline factors and treatment-
associated efﬁcacy changes in type 2 diabetes.
RESEARCHDESIGNANDMETHODS — Multivariableanalysesoftreatmentresponse
in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe/simvastatin
or atorvastatin in a randomized double-blind 6-week study.
RESULTS — Increasingagewasrelatedtoimprovementsinalllipidassessments.Menhadgreater
triglyceride and non-HDL cholesterol reductions than women, and black/Hispanic patients had less
favorablelipideffectsthanotherraces/ethnicities.IncreasingbaselineLDLcholesterolwasassociated
with improvements in most lipids; higher baseline non-HDL cholesterol with improved HDL cho-
lesterol and triglycerides; higher baseline HDL cholesterol with greater non-HDL cholesterol and
high-sensitivity C-reactive protein (hs-CRP) reductions; and higher baseline hs-CRP with smaller
LDL cholesterol, non-HDL cholesterol, and apolipoprotein B reductions. Patients with high baseline
non-HDL cholesterol or triglycerides less frequently attained LDL cholesterol targets. Obesity was
inversely related to HDL cholesterol and hs-CRP changes, and higher baseline A1C to smaller apo-
lipoprotein B reductions. Metabolic syndrome was not a signiﬁcant predictor.
CONCLUSIONS — Treatment responses in type 2 diabetic patients were related to baseline
factors,althoughtreatmenteffects(ezetimibe/simvastatinbeingmoreeffectivethanatorvastatin)
remained consistent. The presence of predictive factors should be considered in planning lipid-
altering therapy.
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T
reatment response to statins can
varyinpatientswithtype2diabetes,
attributed to various patient-related
characteristics, including demographic
and metabolic factors, baseline lipid lev-
els, genetic polymorphisms, and the met-
abolic syndrome (MetS) (1–6). This
analysis explored relationships between
various baseline characteristics and
changes in lipids and high-sensitivity C-
reactiveprotein(hs-CRP)inthepresence/
absence of MetS in the Vytorin versus
Atorvastatin in Patients With Type 2 Dia-
betes Mellitus and Hypercholesterolemia
(VYTAL) study (7).
RESEARCH DESIGN AND
METHODS— This was a post hoc
analysis of the randomized double-blind
6-week VYTAL study in 1,229 type 2 di-
abeticpatientswithhypercholesterolemia
who received ezetimibe/simvastatin
(10/20 mg/day) versus atorvastatin (10
and 20 mg/day) or 10/40 mg ezetimibe/
simvastatin versus 40 mg atorvastatin (7).
Type 2 diabetic patients, 18–80 years,
with A1C levels 8.5%, triglycerides
4.52mmol/l,andLDLcholesterollevels
2.59 mmol/l were included.
This analysis was performed in ran-
domized patients who had baseline and
one or more postbaseline measurements
(modiﬁed-intent-to-treatpopulation)(7).
Prespeciﬁed baseline factors found signif-
icantbyunivariateanalysisforassociation
with week 6 percent changes from base-
line in lipids and hs-CRP were assessed in
multivariablelinearregressionmodelsus-
ing continuous and categorical variables
in separate analyses. Factors were identi-
ﬁed for inclusion in the ﬁnal model using
a model-based variable deletion process.
Triglycerides and hs-CRP were analyzed
in this model using normal-score rank
transformations for percent changes. Pro-
portionsofpatientsattainingprespeciﬁed
LDLcholesterollevels(1.81and2.59
mmol/l)wereassessedusingsimilarlogis-
tic regression models.
RESULTS— Baseline characteristics
and levels of efﬁcacy parameters at baseline
and study end are provided in the online
appendix (supplementary Tables A and
B, available at http://care.diabetesjournals.
org/cgi/content/full/dc09-1762/DC1) (7).
Baseline factors found to be signiﬁcant
predictors of percent change by univariate
analysis (supplementary Table C) were fur-
ther assessed by multivariable analysis. Re-
sults of the analyses of baseline predictors
on percent changes from baseline are dis-
played in Fig. 1 and supplementary Fig. S1
(categorical) and supplementary Table D
(continuous). Increasing age was signiﬁ-
cantly related to all efﬁcacy parameters an-
alyzed except hs-CRP. Patients aged 65
vs. 65 years had greater reductions from
baseline in LDL cholesterol, non-HDL cho-
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 5, MAY 2010 1021Figure 1—Multivariable association of categorical factors with the percent change from baseline in LDL cholesterol (LDL-C) (A), HDL cholesterol
(HDL-C) (B), non–HDL cholesterol (C), and apolipoprotein B (D). P values (*P  0.05, **P  0.01, ***P  0.001) in A–D correspond to the
signiﬁcance of marked (*) category compared with lowest category for the variable. Association (logistic regression) of categorical factors with the
attainmentofLDLcholesterol2.59mmol/l(100mg/dl)(E)and1.81mmol/l(70mg/dl)(F)isshown.(Note:Whennon-HDLcholesterolwas
removed from the multivariable model, baseline LDL cholesterol was a signiﬁcant factor for attainment of these LDL cholesterol levels, presumably
becauseofthehighcorrelation[r0.90]ofbaselinenon-HDLcholesterolwithbaselineLDLcholesterollevels.)GandH:Proportionofpatientswho
attainedLDLcholesterol1.81mmol/l(70mg/dl)bythenumberofpositivepredictivefactorsinthemultivariatemodel.Thefourbaselinefactors
associated with LDL cholesterol 1.81 mmol/l, i.e., age 65 years, baseline triglycerides 1.70 mmol/l (150 mg/dl), baseline non-HDL
cholesterol 4.14 mmol/l (160 mg/dl), and race/ethnicity other than black or Hispanic, are shown in G. The four baseline factors additionally with
ezetimibe/simvastatin (vs. atorvastatin) treatment are shown in H. n  the number of patients with the indicated number of positive factors in the
category of all patients assessed for that number. To convert mmol/l to mg/dl, divide by 0.0259. BL, baseline. TG, triglyceride.
Baseline factors in diabetic dyslipidemia
1022 DIABETES CARE, VOLUME 33, NUMBER 5, MAY 2010 care.diabetesjournals.orglesterol,apolipoproteinB,andtriglycerides;
better LDL cholesterol target attainment;
andlargerHDLcholesterolandapolipopro-
tein A-I increases. Black/Hispanic patients
had smaller LDL cholesterol, non-HDL
cholesterol, and apolipoprotein B reduc-
tions and less LDL cholesterol target attain-
ment than white/other races/ethnicities.
Men had greater triglyceride and non-HDL
cholesterolreductionsthanwomen.Higher
baseline LDL cholesterol was associated
with greater reductions in most lipids as
well as smaller HDL cholesterol increases
and triglyceride reductions and increasing
baseline non-HDL cholesterol with im-
provementsinHDLcholesterolandtriglyc-
erides. Higher baseline HDL cholesterol
was related to greater non-HDL cholesterol
and hs-CRP reductions and smaller HDL
cholesterol and apolipoprotein A-I in-
creases. Patients with higher baseline non-
HDL cholesterol or triglycerides attained
LDL cholesterol targets less frequently.
Higher baseline hs-CRP levels were related
to smaller LDL cholesterol, non-HDL cho-
lesterol, and apolipoprotein B reductions
and larger hs-CRP reductions. Higher base-
line BMI was associated with smaller HDL
cholesterol increases and hs-CRP reduc-
tions and higher baseline A1C with smaller
apolipoprotein B reductions. The presence
of MetS had no effect. Ezetimibe/simvasta-
tin treatment (versus atorvastatin) was
associated with signiﬁcantly greater im-
provements in all efﬁcacy variables.
The likelihood of attaining LDL cho-
lesterol 1.81 mmol/l was related to the
number of positive predictive baseline
factors (Fig. 1G and H). Approximately
31% of patients with zero or one factor
achieved LDL cholesterol 1.81 mmol/l
compared with 46.4% with two factors,
61.5%withthreefactors,74.2%withfour
factors, and 100% with all ﬁve factors.
Without the treatment factor in the
model, 41.6% with zero to one factor and
75.9% with all four factors achieved LDL
cholesterol 1.81 mmol/l.
CONCLUSIONS — In this study, age
and race/ethnicity signiﬁcantly predicted
LDL lowering, consistent with previous
ﬁndings in statin-treated patients (4,5,8).
These effects were not attributable to dif-
ferences in study therapy adherence,
which was high for both age (98.1–
98.2%) and race/ethnicity (95.9–98.7%)
subgroups. Alterations in LDL metabo-
lism (e.g., diminished VLDL particle pro-
duction)mayaccountforthemorerobust
therapeutic LDL cholesterol lowering in
older patients (9,10). Attenuated LDL
cholesterol–lowering responses in black
patients after statin treatment have been
linked to single-nucleotide polymor-
phisms in HMG-CoA reductase (11). The
age-associated HDL cholesterol increases
observed in this study may reﬂect altered
HDL-mediated cholesterol efﬂux and/or
other physiological functions in older pa-
tients (12).
The diminished LDL cholesterol–
lowering response observed in hypertri-
glyceridemic patients may be attributed
totheincreasedprevalenceofsmalldense
LDL particles in these patients that bind
less effectively to LDL receptors (5,6).
Higher baseline HDL cholesterol levels
were negatively related to percent change
from baseline in HDL cholesterol, as re-
portedpreviously(5).WhetherMetSpro-
vides greater clinical value than its
individual components is debated (13).
In this analysis, factors that contribute to
MetS (BMI, A1C, triglycerides, HDL cho-
lesterol)andtheinﬂammatorymarkerhs-
CRP were signiﬁcant predictors of lipid
changes; however, MetS itself was not re-
lated to treatment responses, although
there were relatively few subjects without
MetS(2,3,6).Higherbaselinehs-CRPlev-
els were associated with attenuated LDL
cholesterol lowering, an effect not previ-
ously noted to our knowledge, and per-
haps related to heightened levels of
inﬂammation (9). Obesity-related
changes in HDL cholesterol metabolism
may account for the smaller HDL choles-
terolincreasesassociatedwithhigherBMI
(5,14). Because adipose tissue inﬂamma-
tion in obese patients may strongly inﬂu-
ence hs-CRP levels, smaller hs-CRP
reductions observed in obese patients
could reﬂect lesser statin effectiveness in
suppressing adipose versus vascular
sources of inﬂammation (6,9). The asso-
ciation between increasing baseline A1C
and smaller apolipoprotein B reductions
may be related to the presence of small
dense LDL particles in these patients that
vary inversely with A1C levels (15).
When considered cumulatively, the
baseline factors positive for treatment re-
sponse, namely age 65 years, baseline
triglycerides 1.7 mmol/l, baseline non-
HDLcholesterol4.14mmol/l,andrace/
ethnicity other than black/Hispanic,
predicted attainment of LDL cholesterol
1.81 mmol/l irrespective of treatment.
These results indicated that black or His-
panic subjects, individuals aged 65
years, and patients with elevated triglyc-
erides and non-HDL cholesterol levels
may require more intensive therapy to at-
tain LDL cholesterol goal than patients
without these factors.
It should be noted this exploratory
analysis had limited statistical power, and
some observations may have been inﬂu-
enced by chance variation because of
multiple comparisons. Nonetheless, sev-
eral observations, notably the impact of
ageandrace/ethnicity,areconsistentwith
previous statin studies. In summary, pa-
tient-related characteristics can inﬂuence
efﬁcacy in type 2 diabetic patients with
hypercholesterolemia after ezetimibe/
simvastatin and atorvastatin treatment.
These factors, and particularly the collec-
tive presence of positive predictors,
should be considered in planning lipid-
altering therapies in these patients.
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